This case of advanced lung adenocarcinoma patient was transformed to SCLC resistant to one generation EGFR TKIs treatment, and the front-line treatment after transformation was a regimen of anlotinib in combination with EP, which resulted in the patient achieving a long PFS. This evidence concerns the gene EGFR and lung adenocarcinoma.